ICHD is not just for primary headaches. It covers secondary headaches too. check the following link to access ICHD3. journals.sagepub.com/toc/cepa/38/1 #ichd3matters #headache #migraine #neurology #brain #pain #neuroscience

Tension-type headache and to higher degree the chronic type is associated with decreased health-related quality of life measured with SF-12 #headache Check our latest paper 👉 bit.ly/3q839P5

Management of depression and anxiety in migraine patients may improve headache-related disability. Read the following paper for more information. pubmed.ncbi.nlm.nih.gov/33448374/ #education #migraine #headache #depression #anxiety #IHS #disability

Extracranial injections of #onabotulinumtoxinA shorten cortical depression period without affecting induction, occurrence, or propagation of #CSD. Peripherally applied onabotulinumtoxinA alters a neuronal function in #CNS #botox #migraine PAIN Journal bit.ly/37xotWT

Seven days after injecting #onabotulinumtoxinA to the scalp, we found cleaved #SNAP25 in intracranial meningeal nerve fibers. We suspect that the cleaved SNAP25 reached the #dura through suture branches of dural nerves. PAIN Journal #migraine #headache👉bit.ly/37xotWT

Our latest extensive review on tension-type headache #headache #tensiontypeheadache Nature Reviews Disease Primers 👇

Chronification of tension-type #headache involves sensitization of #spinal and supraspinal #neurons, and decreased antinociceptive activity from the brain go.nature.com/2Pn2VpU

Position number 6: we find our PrimeView on Tension-type #headache. #BestOf2021 go.nature.com/3feRWtw

Gfrerer et al. shed new light on how onabotulinumtoxinA helps prevent occipital headache and neck pain. bit.ly/3zhxDnf

Our data shows that narrow band #green light reduces migrainous headache, #photophobia, #anxiety and improves sleep in majorly of patients with #migraine #AANAM 2022 Dr. Rami Burstein

.Cephalalgia International Headache Society Arne May - Open Access for Cephalalgia read the editorial - doi.org/10.1177/033310…

Lisa Gfrerer and colleagues including BIDMC Headache Center Dr. Rami Burstein demonstrated that in responders, onabotA reduces proinflammatory gene expression and immune cell density mainly in calvarial periosteum and less so in neck muscles and fascia #migraine #Inflammation #painrelief

Headache diary is an important tool that can assist the #diagnosis of medication overuse #headache, help to monitor frequency of headache and track the medication use #migraine #diagnostic

Proposed explanation for why and how non-ictal #allodynia interferes with ability of CGRP monoclonal antibody, #galcanezumab, to prevent initiation of next headache. This may have clinical implications. #migraine #CGRP Cephalalgia In our latest study👉bit.ly/3IkP7W0

Our study in Cephalalgia shows presence/absence of non-ictal #allodynia can be used to identify #galcanezumab responders with close to 80% accuracy and galcanezumab non-responders with close to 85% accuracy #migraine #headache #CGRP American Headache Society 👉 bit.ly/3XvS36k

"Non-ictal cephalic allodynia can be used to predict galcanezumab responders with nearly 80% accuracy and galcanezumab non-responders with nearly 85% accuracy". Find out more at: doi.org/10.1177/033310… #migraine #headache #ichd3matters

Predicting response to anti-CGRP mABs. This study found that older age, fewer prior treatment failures and no past history of immuno-rheumatologic disease may be associated with a better response to aforementioned therapy. rdcu.be/c7q7N #migraine #headache

It is now time to redirect the flow of #training in #headache research starting with onsite clinical #education in areas lacking a solid background. #OneHealthForHeadaches mdpi.com/1660-4601/20/6…

Even a mild decrease in #migraine frequency by CGRP monoclonal antibody, #galcanezumab, is sufficient to partially reverse the excitability and responsivity of #neurons involved in generation of certain #triggers and potentially #premonitory symptoms 👉 bit.ly/3lfFqzw

A CGRP monoclonal antibody, #galcanezumab, reduced incidence of #headache after occurrence of common premonitory symptoms and triggers in those patients in which it reduced migraine frequency by>30,>50 and>70%, but not by<30% NeuroPsychBMC #migraine 👇 …alofheadacheandpain.biomedcentral.com/articles/10.11…